Related Experiment Videos
Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the
N Waters1, C Lundgren, L O Hansson
1Department of Physiology and Pharmacology, University of Göteborg, Sweden.
Journal of Neural Transmission (Vienna, Austria : 1996)
|January 1, 1996
Summary
This study investigated NMDA receptor antagonists and dopamine. Results suggest that NMDA antagonist-induced psychotic symptoms in humans are not caused by increased dopamine release.
Area of Science:
- Neuroscience
- Pharmacology
- Neurochemistry
Background:
- N-methyl-D-aspartate (NMDA) receptor antagonists are known to affect neurotransmission.
- Some NMDA antagonists have been associated with psychotic symptoms in humans.
Purpose of the Study:
- To investigate the effects of NMDA receptor antagonists D-CPPene and CGS 19755 on dopamine transmission and motor activity.
- To determine if NMDA antagonist-induced psychotic symptoms are linked to increased dopamine release.
Main Methods:
- Assessed dopamine (DA) release using mouse brain 3-methoxytyramine (3-MT) levels and rat striatal microdialysis.
- Measured brain tissue levels of DA, DOPAC, HVA, 5-HT, and 5-HIAA in mice and rats.
- Monitored locomotor activity in conjunction with neurochemical measurements.
Main Results:
- In mice, both D-CPPene and CGS 19755 decreased striatal 3-MT levels.
- In rats, CGS 19755 decreased striatal DA but increased 5-HIAA during periods of heightened locomotor activity.
- No significant alterations in limbic forebrain 3-MT levels were observed in mice.
Conclusions:
- The study suggests that the psychotic symptoms observed in humans treated with D-CPPene and CGS 19755 are not a consequence of elevated central dopamine release.
- Findings contribute to understanding the neurochemical underpinnings of NMDA antagonist side effects.